Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 28 5 2019
medline: 2 6 2020
entrez: 25 5 2019
Statut: ppublish

Résumé

NK cells have an important role in immunosurveillance of multiple myeloma (MM) progression, and their activity is enhanced by combination therapies able to regulate the expression of specific activating ligands. Liver X receptors (LXRs) are nuclear receptors and important regulators of intracellular cholesterol and lipid homeostasis. Moreover, they have regulatory roles in both cancer and immune response. Indeed, they can regulate inflammation and innate and acquired immunity. Furthermore, LXR activation directly acts in cancer cells (

Identifiants

pubmed: 31125275
doi: 10.1096/fj.201900319R
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Liver X Receptors 0
MHC class I-related chain A 0
MICB antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9489-9504

Auteurs

Maria Teresa Bilotta (MT)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Maria Pia Abruzzese (MP)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Rosa Molfetta (R)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Gianluca Scarno (G)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Cinzia Fionda (C)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Alessandra Zingoni (A)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Alessandra Soriani (A)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Tina Garofalo (T)

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Maria Teresa Petrucci (MT)

Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy.

Maria Rosaria Ricciardi (MR)

Department of Clinical and Molecular Medicine, Hematology, Sapienza University of Rome, Rome, Italy.

Rossella Paolini (R)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Angela Santoni (A)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Istituto Pasteur-Fondazione Cenci Bolognetti, Rome, Italy.
Istituto Mediterraneo di Neuroscienze Neuromed, Pozzilli, Italy.

Marco Cippitelli (M)

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH